000258682 001__ 258682
000258682 005__ 20240326115540.0
000258682 0247_ $$2doi$$a10.1038/s41531-023-00542-9
000258682 0247_ $$2pmid$$apmid:37322068
000258682 0247_ $$2pmc$$apmc:PMC10272115
000258682 0247_ $$2altmetric$$aaltmetric:150102263
000258682 037__ $$aDZNE-2023-00655
000258682 041__ $$aEnglish
000258682 082__ $$a610
000258682 1001_ $$aDüchs, Matthias$$b0
000258682 245__ $$aAAV-mediated expression of a new conformational anti-aggregated α-synuclein antibody prolongs survival in a genetic model of α-synucleinopathies.
000258682 260__ $$aLondon [u.a.]$$bNature Publ. Group$$c2023
000258682 3367_ $$2DRIVER$$aarticle
000258682 3367_ $$2DataCite$$aOutput Types/Journal article
000258682 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1711372566_22709
000258682 3367_ $$2BibTeX$$aARTICLE
000258682 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000258682 3367_ $$00$$2EndNote$$aJournal Article
000258682 520__ $$aPrion-like transmission of pathology in α-synucleinopathies like Parkinson's disease or multiple system atrophy is increasingly recognized as one potential mechanism to address disease progression. Active and passive immunotherapies targeting insoluble, aggregated α-synuclein are already being actively explored in the clinic with mixed outcomes so far. Here, we report the identification of 306C7B3, a highly selective, aggregate-specific α-synuclein antibody with picomolar affinity devoid of binding to the monomeric, physiologic protein. 306C7B3 binding is Ser129-phosphorylation independent and shows high affinity to several different aggregated α-synuclein polymorphs, increasing the likelihood that it can also bind to the pathological seeds assumed to drive disease progression in patients. In support of this, highly selective binding to pathological aggregates in postmortem brains of MSA patients was demonstrated, with no staining in samples from other human neurodegenerative diseases. To achieve CNS exposure of 306C7B3, an adeno-associated virus (AAV) based approach driving expression of the secreted antibody within the brain of (Thy-1)-[A30P]-hα-synuclein mice was used. Widespread central transduction after intrastriatal inoculation was ensured by using the AAV2HBKO serotype, with transduction being spread to areas far away from the inoculation site. Treatment of (Thy-1)-[A30P]-hα-synuclein mice at the age of 12 months demonstrated significantly increased survival, with 306C7B3 concentration reaching 3.9 nM in the cerebrospinal fluid. These results suggest that AAV-mediated expression of 306C7B3, targeting extracellular, presumably disease-propagating aggregates of α-synuclein, has great potential as a disease-modifying therapy for α-synucleinopathies as it ensures CNS exposure of the antibody, thereby mitigating the selective permeability of the blood-brain barrier.
000258682 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000258682 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000258682 7001_ $$aBlazevic, Dragica$$b1
000258682 7001_ $$aRechtsteiner, Philipp$$b2
000258682 7001_ $$00009-0003-7173-1177$$aKenny, Cynthia$$b3
000258682 7001_ $$aLamla, Thorsten$$b4
000258682 7001_ $$aLow, Sarah$$b5
000258682 7001_ $$aSavistchenko, Jimmy$$b6
000258682 7001_ $$0P:(DE-2719)2810592$$aNeumann, Manuela$$b7$$udzne
000258682 7001_ $$00000-0003-0000-7096$$aMelki, Ronald$$b8
000258682 7001_ $$aSchönberger, Tanja$$b9
000258682 7001_ $$aStierstorfer, Birgit$$b10
000258682 7001_ $$aWyatt, David$$b11
000258682 7001_ $$00000-0001-9311-0628$$aIgney, Frederik$$b12
000258682 7001_ $$00000-0003-0724-0798$$aCiossek, Thomas$$b13
000258682 773__ $$0PERI:(DE-600)2819218-7$$a10.1038/s41531-023-00542-9$$gVol. 9, no. 1, p. 91$$n1$$p91$$tnpj Parkinson's Disease$$v9$$x2373-8057$$y2023
000258682 8564_ $$uhttps://www.nature.com/articles/s41531-023-00542-9
000258682 8564_ $$uhttps://pub.dzne.de/record/258682/files/DZNE-2023-00655.pdf$$yOpenAccess
000258682 8564_ $$uhttps://pub.dzne.de/record/258682/files/DZNE-2023-00655.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000258682 909CO $$ooai:pub.dzne.de:258682$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000258682 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810592$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000258682 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000258682 9141_ $$y2023
000258682 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-29
000258682 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-10-13T14:34:28Z
000258682 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-29
000258682 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-29
000258682 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNPJ PARKINSONS DIS : 2022$$d2023-08-29
000258682 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:11:33Z
000258682 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-03-31
000258682 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:11:33Z
000258682 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-29
000258682 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-29
000258682 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000258682 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T15:11:33Z
000258682 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-03-31
000258682 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNPJ PARKINSONS DIS : 2022$$d2023-08-29
000258682 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-03-31
000258682 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-29
000258682 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-03-31
000258682 9201_ $$0I:(DE-2719)1210003$$kAG Neumann$$lMolecular Neuropathology of Neurodegenerative Diseases$$x0
000258682 980__ $$ajournal
000258682 980__ $$aVDB
000258682 980__ $$aUNRESTRICTED
000258682 980__ $$aI:(DE-2719)1210003
000258682 9801_ $$aFullTexts